Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175330 | 0.83 | ALDH1A1 (0.46) | ADORA3ADORA2AADORA1ALDH1A1MEN1 | |
| SCHEMBL9543825 | 0.83 | ALDH1A1 (0.42) | ADORA3ADORA2AADORA1ALDH1A1MEN1 | |
| SCHEMBL12429197 | 0.83 | TEAD2 (0.45) | ADORA3ADORA2AADORA1ALDH1A1MEN1 | |
| SCHEMBL4698208 | 0.82 | TSHR (0.50) | ADORA3ADORA2AADORA1ALDH1A1MEN1 | |
| SCHEMBL11564068 | 0.82 | F2 (0.52) | ADORA3ADORA2AADORA1ALDH1A1KMT2A | |
| SCHEMBL3267578 | 0.82 | TSHR (0.50) | ADORA3ADORA2AADORA1ALDH1A1MEN1 | |
| SCHEMBL17785298 | 0.82 | ALDH1A1 (0.45) | ADORA2AADORA1ALDH1A1MEN1KMT2A | |
| SCHEMBL20098494 | 0.81 | ADORA3 (0.55) | ADORA3ADORA2AADORA1ALDH1A1MEN1 | |
| SCHEMBL1459312 | 0.81 | ADORA2A (0.55) | ADORA3ADORA2AADORA1ALDH1A1HSD17B10 | |
| SCHEMBL31714887 | 0.81 | TEAD2 (0.43) | ADORA3ADORA2AADORA1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178265-A | Synthesis method of 3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxylic acid | 常州工程职业技术学院 | 2023-05-30 | — | — | CN | claimed |
| JP-6056793-A | — | — | None | — | — | JP | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735114-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2026-05-06 | — | — | EP | disclosed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025002491-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | MASARYKOVA UNIVERZITA (CZ) | 2025-01-02 | — | — | WO | disclosed |
| EP-0588299-A2 | 1,2,4-Oxadiazolyl- or 1,2,4-thiadiazolyl-biphenyl derivatives as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-23 | — | — | EP | disclosed |
| JP-H0656793-A | A PYRAZOLE SULFONYLUREA DERIVATIVE, ITS PRODUCTION AND SELECTIVE HERBICIDE CONTAINING THE SAME | NISSAN CHEM IND LTD | 1994-03-01 | — | — | JP | disclosed |
| EP-0537423-A1 | N-pyrazolyl-1,2,4-triazolo(1,5-c)pyrimidine-2-sulfonamide herbicides | DowElanco (US) | 1993-04-21 | — | — | EP | disclosed |
| US-5201938-A | N-pyrazolyl-1,2,4-triazolo[1,5-c]pyrimidine-2-sulfonamide herbicides | DOWELANCO (US) | 1993-04-13 | — | — | US | disclosed |
| US-4689417-A | HERBICIDE INTERMEDIATES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-25 | — | — | US | disclosed |
| US-4668277-A | HERBICIDES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1987-05-26 | — | — | US | disclosed |
| US-4542131-A | NERVOUS SYSTEM DISORDERS | LILLY INDUSTRIES LIMITED (GB) | 1985-09-17 | — | — | US | disclosed |
| US-4486591-A | CNS DISORDERS | LILLY INDUSTRIES LIMITED (GB) | 1984-12-04 | — | — | US | disclosed |
| US-4404137-A | NEUROLEPTIC AGENTS; SEDATIVES; TRANQUILIZERS; ANTIEMETICS | LILLY INDUSTRIES LIMITED (GB) | 1983-09-13 | — | — | US | disclosed |
| EP-0027390-A1 | Novel benzodiazepine compounds, their preparation, intermediates employed in their preparation, and pharmaceutical compositions containing them | Lilly Industries Limited (GB) | 1981-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ADORA3 205/4885ADORA2A 249/4885ADORA1 162/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | ADORA3 2185/4885ADORA2A 3226/4885ADORA1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.